Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data Klaviyo, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2023
FY2023
FY2024
FY2025
Revenue
291
473
698
937
1,234
Cost of revenue
84.7
128
178
221
313
Gross profit
206
345
520
716
921
Research and development
65.6
104
262
238
291
Selling and marketing
156
214
394
404
506
General and administrative
63.2
81.8
194
158
192
Operating expenses
285
400
851
800
989
Operating income
-79.2
-55
-331
-84.1
-67.8
Interest expense
0.01
0
0
Interest income
0.14
5.54
24.1
39.6
39.4
Other non-operating income
0.16
5.93
23.6
40.4
37.2
Pre-tax income
-79.1
-49.1
-307
-43.7
-30.5
Income tax
0.32
0.08
1.19
2.46
1.25
Net income
-79.4
-49.2
-308
-46.1
-31.8
EBITDA
-74
-46
-317
-66.4
-49.2
EPS, basic
-0.36
-0.21
-1.27
-0.17
-0.11
EPS, diluted
-0.36
-0.21
-1.27
-0.17
-0.11
Shares, basic (weighted)
221
230
243
266
291
Shares, diluted (weighted)
221
230
243
266
291
Balance sheet
FY2021
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
328
386
739
881
1,065
Receivables
10.7
23.1
43.1
60.7
Other current assets
19.3
26.2
34.3
50.1
Total current assets
428
803
980
1,206
Property, plant and equipment
45.8
43.5
48.2
80.3
Lease right-of-use assets
45.7
37
42.9
101
Other non-current assets
8.96
7.42
15.8
12.4
Total assets
629
1,089
1,273
1,581
Accounts payable
8.89
13.6
14.6
29.1
Accrued liabilities
36.1
62.8
99.8
125
Deferred revenue
25.1
40.1
64.5
103
Total current liabilities
85
131
200
282
Lease liabilities
47.5
37.5
32.4
96
Other non-current liabilities
0.88
6.16
6.98
5.82
Total liabilities
133
174
239
384
Paid-in capital
1,249
1,714
1,879
2,073
Retained earnings
-2,285
-799
-845
-877
Shareholders' equity
-2,236
-1,036
915
1,034
1,197
Total equity
-2,236
-1,036
915
1,034
1,197
Total liabilities and equity
629
1,089
1,273
1,581
Cash flow statement
FY2021
FY2023
FY2023
FY2024
FY2025
Net income
-79.4
-49.2
-308
-46.1
-31.8
Depreciation and amortization
5.27
9.04
13.7
17.7
18.6
Stock-based compensation
35.2
6.8
341
135
162
Deferred income tax
0.1
-0.07
-3.43
0.56
-3.06
Change in receivables
-5.09
-5.16
-12.9
-20.8
-19.7
Change in payables
23.9
-21.1
4.51
0.11
12
Cash from operations
-22.7
-23.6
119
166
218
Capital expenditures
-13
-15.8
-3.65
-5.92
-9.49
Acquisitions
0
-0.5
0
0
-2.03
Cash from investing
-14.2
-18.7
-9.36
-17.2
-30.5
Stock issued
346
99.6
0
0
0
Share buybacks
-140
0
0
Cash from financing
211
101
243
-5.8
-4.49
Net change in cash
174
59
353
143
183
Free cash flow
-35.8
-39.4
116
160
209
Interest paid
0.01
0
0
Income taxes paid
0.07
0.2
0.28
4.69
6.54
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $15.80 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
73.8%
Gross profit / revenue.
Operating margin
-1.9%
Operating income / revenue.
EBITDA margin
-0.2%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
0.8%
Pre-tax income / revenue.
Net margin
0.5%
Net income / revenue.
FCF margin
18.2%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
19.9%
Cash from operations / revenue.
Effective tax rate
36.7%
Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)
0.7%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
0.5%
Net income / average total assets.
Return on invested capital (ROIC)
-12.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
23.1%
Research and development expense / revenue.
Stock-based pay / revenue
12.3%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
1.7%
Capital expenditures / revenue.
D&A / revenue
1.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
31.6%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
37.7%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
28.7%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
38.8%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow growth, 1y
31.4%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y
30.3%
Free cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
15.7%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
24.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
35.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
9.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
8.2%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.13x
Current assets / current liabilities.
Quick ratio
2.83x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.58x
(Cash + short-term investments) / current liabilities.
Free cash flow / net income, when net income is positive.
Capex / operating cash flow
8.3%
Capital expenditures / cash from operations, when that is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
$0.02
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$4.68
Revenue / diluted weighted shares.
FCF per share
$0.85
Free cash flow / diluted weighted shares.
Operating cash flow per share
$0.93
Cash from operations / diluted weighted shares.
Book value per share
$3.26
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
662x
Market cap / net income. Only when net income is positive.
P/S
3.24x
Market cap / revenue.
P/B
4.65x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.65x
Market cap / tangible book value, when positive.
P/FCF
17.8x
Market cap / free cash flow. Only when free cash flow is positive.
P/OCF
16.3x
Market cap / cash from operations, when positive.
EV/Sales
2.64x
Enterprise value / revenue.
EV/FCF
14.5x
Enterprise value / free cash flow, when both are positive.
FCF yield
5.6%
Free cash flow / market cap.
Earnings yield
0.2%
Net income / market cap (the inverse of P/E).
What was Klaviyo, Inc.'s revenue in fiscal 2025?
Klaviyo, Inc. reported revenue of $1.23B for fiscal 2025, 31.6% higher than the year before.
Was Klaviyo, Inc. profitable in fiscal 2025?
No. It reported a net loss of $31.8M.
How much free cash flow did Klaviyo, Inc. generate in fiscal 2025?
Cash from operations of $218.0M minus capital expenditures of $9.5M left free cash flow of $208.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.